Influence of the duration of psoriatic arthritis on the achievement of remission and minimal disease activity during therapy with genetically engineered biologic drugs. Data from the all-russian register of patients with psoriatic arthritis

Influence of the duration of psoriatic arthritis on the achievement of remission and minimal disease activity during therapy with genetically engineered biologic drugs. Data from the all-russian register of patients with psoriatic arthritis

Aim. To study the frequency and timing of the onset of remission and minimal disease activity after the administration of genetically engineered biologic drugs (GEBD) in patients with early and long-term psoriatic arthritis observed within the framework of the All-Russian register of patients with p...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavskiy, I. N. Kushnir, I. F. Umnova, S. S. Kudishina, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2021-01-01
Series:Научно-практическая ревматология
Subjects:
early psoriatic arthritis
genetically engineered biologic drugs
remission
minimal disease activity
Online Access:https://rsp.mediar-press.net/rsp/article/view/2970
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items